Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmiNA neoadjuvant study of amivantamab with lazertinib or chemotherapy in resectable EGFR-mutant NSCLC
CTR20262095Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, lazertinib, carboplatin, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262095.